Australian antiviral developer Island Pharmaceuticals (ASX:ILA) has been granted US Patent Number 12,508,266 by the US Patent and Trademark Office for the use of Galidesivir in the treatment of filoviridae viruses, including Ebola and Marburg.
The patent, which provides protection through 14 October 2031, covers a broad range of claims for administering therapeutically effective doses of Galidesivir to combat infections caused by this family of single-stranded negative-sense RNA viruses.
The approval strengthens Island’s growing intellectual property portfolio, acquired as part of its Galidesivir program, and aligns with the company's clinical development strategy, including the FDA’s November 2025 confirmation of an approval pathway for Marburg treatment under the Animal Rule.
Filoviridae viruses are classified by the US Department of Health and Human Services as biological select agents, posing a significant threat to public health.
This follows last month’s USPTO grant of patent number 12,472,197, which secured US protection for Galidesivir in the treatment of COVID-19.
CEO Dr. David Foster said the new patent "demonstrates the strength of our IP footprint and directly supports our clinical development pathway for Marburg, providing a solid foundation to expand our intellectual property alongside ongoing studies."
At the time of reporting, Island Pharmaceuticals' share price was $0.46.